Screening for chronic viral hepatitis in migrant populations · PDF fileimprove the awareness, understanding and health-seeking behaviour of this audience ... migrant and ethnic minority

20101105_D02-03_PMT_EN_PS.pdf

1

Screening for chronic viral hepatitis

in migrant populations

Communication and Dissemination Strategy

Final Version: June 2012

20101105_D02-03_PMT_EN_PS.pdf

2

Table of Contents:

Introduction 3

Rationale 4

Purpose and objectives of a communications strategy 5

Stakeholder analysis 6-7

Target Audiences 8

Key Messages 9-10

Dissemination Plan 11-12

Dissemination Schedule 13

Distribution and target of project deliverables 14

Conference and events calendar 15-18

Internal communications 19

Requirements for external communications 20

20101105_D02-03_PMT_EN_PS.pdf

3

Introduction:

HEPScreen – Screening for hepatitis B and C among migrants in the European Union – is a

collaborative project funded by the EU in the 7th Framework for Health Programme. The

project launched in October 2011 and will continue until September 2014.

The central objective is to assess, describe and communicate to public health professionals

the tools and conditions necessary for implementing successful screening programmes for

hepatitis B and C among migrants in the European Union. By doing so, the project aims to

reduce the burden of mortality and morbidity associated with hepatitis B and C in migrant

and ethnic minority populations.

More specifically, the objectives of the project are to:

� Collect and analyse information on screening practices, counselling, health care and

patient management of hepatitis B and C in migrants in the EU;

� Collate examples of effective communication materials aimed at migrant groups to

improve the awareness, understanding and health-seeking behaviour of this audience

in relation to hepatitis B and C;

� Design and field-test four pilot screening programmes in Spain, England, Scotland and

Hungary using systematic, opportunistic and outreach approaches for case detection

of chronic hepatitis B and C;

� To bring together a broad range of stakeholders to build a network and gather

consensus on best practice;

� Integrate the findings and outcomes into practical and policy tools, materials and

documents aimed at public health professionals and policy makers.

Through the achievement of the objectives, the project will lay the foundation for the

expansion of screening and prevention programmes for hepatitis B and C among migrants in

countries of the European Union. It is hoped to stimulate and encourage investment,

intervention and activities relating to hepatitis B and C among migrants in the EU.

20101105_D02-03_PMT_EN_PS.pdf

4

Rationale:

Chronic viral hepatitis B and C are a leading cause of liver cancer and cirrhosis. Worldwide, it

is estimated that about 280 million people are chronically infected with the hepatitis B virus

and 130 million people with the hepatitis C virus.

Migrants from endemic areas are particularly at risk and the conditions represent a

substantial health burden among nearly all migrant groups in Europe. For migrants,

transmission of hepatitis B is primarily from mother to child at birth and in early childhood,

and primarily through blood transfusions in the past and unsafe injections for hepatitis C.

Both conditions are mostly asymptomatic and remain undetected for many years.

Awareness among those at risk and the general public is low, making case detection a

challenge.

Antiviral treatment exists for both hepatitis B and C, slowing progression, delaying the onset

of cirrhosis and reducing the risk of liver cancer. However, awareness among professionals

about treatment options is generally low.

Treatment of eligible patients can prevent a considerable part of the hepatitis-related

burden of disease and death and reduce inequalities in health.

Systematic prevention and control among these often underserved migrant groups has long

been neglected.

20101105_D02-03_PMT_EN_PS.pdf

5

Purpose and objectives of a communications strategy:

The purpose of the Communication and Dissemination Strategy is to formalise and

document how information and results from the project will be disseminated and to who.

Communication refers to the internal flow of information between project partners.

Dissemination refers to the process of making the results and deliverables of a project

available to the stakeholders and to the wider audience. Dissemination is essential for take-

up, and take-up is crucial for the success of the project and for the sustainability of outputs

in the long term.

The objectives of this strategy are:

� To raise awareness of the HEPscreen project and its published work among

professionals, policy makers and patient groups.

� To outline internal communication tools and timescales to faciliate and foster the

effective flow of information between project partners and between work package

teams;

� To increase and maintain the interest of external stakeholders in the project and its

associated topics through the continued and formalised flow of relevant and

appropriate information;

� To establish links and exchange information to expand and empower organisations

and individuals involved and interested in a diverse range of fields including: viral

hepatitis; migrant and ethnic minority health; translating evidence into practice and

knowledge transfer; and improving professional skills and competancies;

This document will:

� Describe the stakeholder analysis undertaken;

� Define target audiences;

� Outline key messages;

� List routes of communication and means/media;

� Provide a framework and schedule for dissemination.

20101105_D02-03_PMT_EN_PS.pdf

6

Stakeholder analysis HEPscreen addresses a complex mix of topics and extensive written output is planned. The

need to engage with a wide range of stakeholders is at the heart of the HepScreen project

and runs throughout the work. This task requires an understanding of who these

stakeholders are, how they work, their existing areas of interest and areas of overlap with

the HepScreen work, their current knowledge of the topic and the relevant named

individuals, amongst other details.

Stakeholder analysis has been used to identify key organizations and individuals that can

influence or affect the progress and long term success of the work, as well as those who will

be affected by it. It also aims to identify those that have an active interest in the work, allies

that could play a guiding role, become ‘knowledge brokers’ and champion the work

throughout.

Stakeholders are categorised by:

� Level of operation:

� International

� European

� National (name of country)

� Name of organization

� Type of organization e.g.:

� Research unit

� EU Agency

� NGO

� Scientific membership network

� UN

� Function / Role

� A description of activities, focus, funding/commissioning /sponsorship

arrangements, host organization etc.

� Key topic area for project relevance

� Health care systems (e.g. The Alliance for Health Policy and Systems

Research)

20101105_D02-03_PMT_EN_PS.pdf

7

� Health policy development and leadership (e.g. WHO)

� Hepatitis (e.g. World Hepatitis Alliance)

� Human Trafficking and HIV/AIDS prevention (e.g. UNGIFT)

� International Development / Pre-migration policy (e.g. Europe Aid)

� Migrants health research and policy development and research (e.g.

ICMHD)

� Public Health Professional Development (e.g. ASPHER)

� Evidence into practice / Knowledge Translation

� Website address

� Named contact and role

� Contact details

20101105_D02-03_PMT_EN_PS.pdf

8

Target Audiences:

Primary audiences:

� Public health and primary care professionals

� Hepatologists

� Public health policy and decision makers – European-level and local, regional,

national within Europe

� Liver patient groups

� Hepatitis patient groups

� Minority and migrant health advocacy groups

� The public health research community

� Evidence into practice / knowledge translation research community

� Health literacy groups and organisations

Secondary audiences:

� The general public

� Professionals and policy makers outside Europe

� Those focused or working on on:

� Migration population and statistics

� Human trafficking policy

� Other at risk population groups such as IDUs, MSM etc.

� Other infctious diseases

20101105_D02-03_PMT_EN_PS.pdf

9

Key Messages

� Viral hepatitis is a serious public health issue. Worldwide, 280 million people are

chronically infected hepatitis B and 130 million people with the hepatitis C virus.

� Viral hepatitis can be very serious. Chronic viral hepatitis is a leading cause of liver

cancer (heptocellular carcinoma (HCC)) and cirrhosis.

� Hepatitis B and C are highly infectious, blood-borne asymptomatic viruses that can go

undected for many years. The hepatitis B virus (HBV) is spread between people

through contact with the blood or other body fluids (i.e. saliva, semen and vaginal

fluid) of an infected person. The hepatitis C virus (HCV) is spread through direct

contact with infected blood. Very rarely it may be passed on through other body

fluids.

� Migrants from hepatitis B and C endemic areas are particularly at risk and the

conditions represent a substantial health burden among nearly all migrant groups in

Europe.

� Reliable data estimating prevalence at a European level among migrant populations

are limited, making the scale of the potential burden of morbidity and mortality

unknown. HEPscreen will identify the main migrant populations in the seven

participant countries and estimate the prevalence within these populations using the

best available data.

� There are a number of transmission routes. For migrants, transmission of hepatitis B

is primarily from mother to child at birth and in early childhood, and primarily

through blood transfusions in the past and unsafe injections for hepatitis C.

� Effective treatment options are available for both hepatitis B and C, slowing

progression, delaying the onset of cirrhosis and reducing the risk of liver cancer.

20101105_D02-03_PMT_EN_PS.pdf

10

� Treatment of eligible patients can prevent a considerable part of the hepatitis-related

burden of disease and death and reduce inequalities in health.

� Examples of best practice programmes that target migrants for screening, referral,

counselling and treatment are limited. HEPscreen will identify and assess examples,

test out four approaches to screening migrant populations and produce tools to

encourage the implementation of new screening programmes based on the best

available evidence.

20101105_D02-03_PMT_EN_PS.pdf

11

Dissemination plan:

Method Measurement Message Audience Timing

HEPscreen

website

� Number of downloads

� Registered subscribers

� Citations

� Links from other sites

� Existence of the project

� Aims, objectives and expected results

� Contact conduit

Policy makers, clinical

managers, decision makers,

researchers, patient groups and

professionals

Ongoing –

launch

March 2012

Newsletter/e-

bulletin

� Number of new subscribers/reach

� Guest contributions (if applicable)

� Citations

� Further (stakeholder-led)

distribution

� News from the field

� News items and progress

� Lessons learned

� Campaign Corner

� Material Updates

� Upcoming Events (training opportunities,

conferences, etc)

� Journal articles/publications




professionals

Quarterly /

Six Monthly

from April

2012

Scientific

journals

� Number of accepted submissions

� Ongoing/further citation

� Use in policy documents and

updated guidelines

� Approaches to present

findings/methods at conferences

� Replication in future work

� Robust conclusions

� Research methods

� Data available

� Strategic context/rationale

� Interpretation and analysis

� Recommendations

Clinical managers, decision

makers, the research

community, GPs, Hepatologists,

public health professionsals

Continuously

from

September

2012

Project

Leaflet

� Quantity distributed

� Number of downloads

� Requests for additional copies

� Citations/references




� Contact conduit




professionals

Ongoing –

launch

March 2012

Survey tool

(WP4)

� Wide distribution

� Response rate

� Response bias

� Diversity of respondents








professionals

June 2012

Presentations

and presence

� Number of approaches made to

HEPscreen to present





As and when

requested /

20101105_D02-03_PMT_EN_PS.pdf

12

at

conferences

and events

� Number of accepted submissions

� Quantity and quality of topics and

geographical distribution


� Data available



� Recommendations


professionals

required.

Practical tools

� Uptake/usage

� Feedback

� Adaptation

� Incorporation into professional

development, guidelines or formal

best practice repositories

� Rationale for action on HBV/HCV among

migrants

� Data sources

� The best evidence available

� Developing robust actions

� Successful implementation

� Challenges, barriers and risks how to

overcome these

� Clear, accessible and appropriate format

Clinical decision makers and

professionals

From May

2014

Policy

summaries

� Incorporation into formal policy

� Citation

� Positive feedback from

policy/decision making community

� Endorsement from professional

bodies, other research institutes

and the scientific community

� New advocacy activities led by

patient groups and campaigners

� Rationale for action on HBV/HCV among

migrants

� Data sources

� The best evidence available

� Developing robust actions

� Successful implementation

� Challenges, barriers and risks how to

overcome these

� Clear, accessible and appropriate format




professionals

Ongoing

from 2013

Articles and

summaries in

other

publications

� Diversity of publications published

in

� Feedback and commentary

� Increased web-traffic and subcribers




� Contact conduit




professionals

As and when

requested /

required

Workshops,

conferences

and events

(HEPscreen as

host)

� Attendance

� Diversity of audience

� Profile of panel members/speakers

� Positivie feedback

� Published summaries




� Data available





professionals

At least two

already

scheduled:

Sept/Oct

2013 and

20101105_D02-03_PMT_EN_PS.pdf

13


� Recommendations

Sept 2014

20101105_D02-03_PMT_EN_PS.pdf

14

Schedule for dissemination:

Method Frequency Months of project Work package and lead

partner

HEPscreen website

Update at least monthy or as an when

new documents or updates become

available.

Continuous from M6 WP1

IV, PdV and AF

Newsletter/e-bulletin Quarterly M7, M10, M13, M16, M19, M22, M25, M28, M31,

M34, M37

WP1

IV and AF

Scientific journals Continuous – at least every six months

from M14 (Nov 2012)

M14, M20, M26, M32 and further publication

beyond end of project

WP4, WP5, WP6 and

WP7

Leaflet

Staged distribution during Y2 (April

2012 (M7) to April 2013 (M19))

New, updated version in late 2013?

Stakeholder distribution:

� Via conferences (see conference timetable)

� With survey tool (M7 – M10)

WP1 and WP2

Presentations and presence

at conferences and events

(not hosted by HEPscreen)

See calendar of events and

conferences.

At least two per year.

See calendar of events WP1, WP2 and WP7

Practical tools Infrequent – final outcome of project M32-36 WP2 and WP7

Policy summaries Infrequent – final outcome of project M32-36 WP2 and WP7

Articles and summaries in

other publications (e.g

EuroHealth, ICMHD

newsletters)

Continuous – at least every six months

from M9 (June 2012) M9, M16, M23, M30, M35. WP1 and WP2

Workshops, conferences

and events (HEPscreen as

host)

At least two planned: integration

workshop September 2013 and

dissemination event planned

September 2014.

M28 and M36 WP5 and WP7

20101105_D02-03_PMT_EN_PS.pdf

15

Distribution and target of project deliverables (D1-10):

D# Title Distribution channel Target Audience

1 Project website (WP1) www; Internet All stakeholders

2 Dissemination products, tools

and channels (WP2)

Web site/ internet/ printed material (consider

fast communication channels) All stakeholders

3 Final project evaluation report

(WP3)

Project web site, link on other international

websites, mailing All stakeholders/WP partners

4

Report on the screening and

clinical management practises of

hepatitis B/C (WP4)

Project web site, link on other international

websites, scientific journal, newsletter

Public health, Policy makers, health care professionals,

Scientists, international/ national migration and Health

organisations

5 Workshop (WP5) Project website, link on other international

websites, mailing, scientific journal Project partners, health care professionals

6 Web based information package

(WP5)

www, project web site, optimal communication

channels defined in the WP5

Migrants, Migrant groups, health care professionals,

International/ national organisations

7 Report on the results of the pilot

studies (WP6)

Project website, link on other international

websites, mailing, scientific journal

Public health, Policy makers, health care professionals,

Scientists, international/national migration organisations

8 Input data for cost-effectiveness

assessment (WP6) Internal communication ECDC (as part of their cost-effectiveness tender)

9 Tool kit and policy

recommendations (WP7)

Project website, link on other international /

national websites,

Public health, Policy makers, health care & migrant

professionals, international/ national migration

organisations

10 Technical and financial reports Project website other channels need to be

defined in WP1 WP partners and also public available

20101105_D02-03_PMT_EN_PS.pdf

16

Conference calendar:

Event name Frequency Organised by Date Audience Description Location URL

Innovation in

Healthcare

without

borders

Ad hoc /

infrequent

DG Research

and

Innovation -

Health

16 - 17 April

2012

Scientists and

clinicians

The main objective of the conference is to act as an innovation in

healthcare policy forum involving the key actors and policy-makers

in order to:

- Identify major challenges and build consensus to address them,

- Develop initiatives and opportunities for Healthcare Innovation;

- Provide continuity with previous events.

Brussels,

Belgium

http://ec.europa.e

u/research/health/

events-13_en.html

International

Liver

Congress

Annual EASL 18 - 22 April

2012

Scientists and

clinicians

An opportunity for clinicians and researchers from developing

countries to present their research and interact with EASL

members. There will also be an excellent opportunity for EASL

members to get up-to-date with the diagnosis and management of

tropical liver diseases at the joint EASL-IASL postgraduate course.

Barcelona

Centre

Convencions

Internacional

(CCIB)

http://www.easl.e

u/_the-

international-liver-

congress/general-

information

World

Congress on

Public Health

Every three

years

WFPHA and

the Ethiopean

Public Health

Assocation

23-27 April,

2012

Research

community,

scientists and

clinicians

Theme: Towards Global Health Equity: Opportunities and Threats

An international forum for the exchange of knowledge and

experiences on key public health issues; Contribute towards

protecting and promoting public health at global, continental, and

national levels; Create a better understanding of Africa's major

public health challenges within the global public health

community; and Facilitate and support the formation of the

African Federation of Public Health Associations (AFPHA)

Addis Ababa,

Ethiopia

http://www.wfpha

.org/

http://www.etpha.

org/2012/

EUNID

Meeting Annual EUNID 24 May 2012

Health care

professionals

To enhance co-operation, communication and exchange of

information Rome, Italy

http://www.eunid.

eu/meetings.asp

Conference

on Migrant

and Ethnic

Minority

Health in

Europe

Annual?

EUPHA, the

CERGAS and

Carlo F.

Dondena

Research

Centres at

Università

Bocconi

21-23 June

2012

Research

community

To compare scientific results and foster best practices to

counteract possible disadvantages of migrants and foreign citizens

as to their health conditions and access to health services.

Milan, Italy

http://www.unibo

cconi.eu/wps/wcm

/connect/SitoPubb

lico_EN/Navigation

+Tree/Home/Depa

rtments/Departme

nt+of+Policy+Anal

ysis+and+Public+M

anagement/Migra

20101105_D02-03_PMT_EN_PS.pdf

17

nt+Health

International

research

conference

on Liver

Cancer

Annual? Various 5-7July, 2012

Research

community,

scientists and

clinicians

Sponsored by the German Research Foundation (DFG), the

European Association for Cancer Research (EACR) and by the

European Association for the Study of the Liver (EASL), organized

and initiated by collaborative Research Centre

The event will cover all research aspects of human liver

carcinogenesis, from its initiation by chronic liver disease to its

progression into metastatic cancer, its functional dissection, and

the identification of novel preventive, diagnostic, and therapeutic

approaches. Poster sessions and workshops will provide ample

opportunities for the discussion of recent research results.

Heidelberg,

Germany

http://congress.cp

b.de/index.php?id

=625

World

Hepatitis Day Annual

World

Hepatitis

Alliance

28 July each

year

All - broad

awareness raising

World Hepatitis Day is supported by patient groups across the

globe. Together with governments, non-governmental

organisations and associations, healthcare professionals,

companies and thousands of individuals and patient groups

coordinate World Hepatitis Day activities

International

/ various.

Local events

encouraged

http://worldhepati

tisalliance.org/Wor

ldHepatitisDay.asp

x

IMISCOE

Annual

Conference

Annual IMISCOE 28-29 August

2012

Researchers and

academia

Mobility as the new paradigmatic perspective in the social

sciences?

Amsterdam,

Netherlands

http://www.imisco

econferences.org/

European

Congress of

Tropical

Medicine and

International

Health

Every two

years

Federation for

European

Societies for

Tropical

Medicine and

International

Health

10-13 Sept

2013

Research

community,

scientists and

clinicians

To create a platform for presenting and discussing all aspects of

International Health; to evaluate the global progress towards

achieving Millenium Development Goals 2015; to examine the

other side of the progress coin: the rapid global growth in non

communicable diseases, with focus on the developing world.

Copenhagen

Denmark

http://www.festmi

h.eu/Page/WebOb

jects/PageFestE.w

oa/wa/displayPage

?name=Home

International

Liver Cancer

Association

Sixth

Conference

Annual

International

Liver Cancer

Association

14-16

September,

2012

Clinical,

translational and

basic researchers,

physicians and

allied

professionals

across liver cancer

related disciplines

Scientific exchange, debate and networking. To share best

practices and findings

Berlin,

Germany

http://www.ilca20

12.org/

20101105_D02-03_PMT_EN_PS.pdf

18

International

Symposium

on Viral

Hepatitis and

Liver Disease

(ISVHLD)

Every three

years

International

Advisory

Board

comprised of

specialists,

clinicians,

researchers

and academia

22-25

September

2012

Research

community,

scientists and

clinicians

Dedicated to bringing together outstanding clinical and basic

researchers in viral hepatitis from around the world to provide

summary updates on advances in the understanding, diagnosis,

prevention, control, and treatment of all five forms of viral

hepatitis. The meeting also provides a venue for reviewing the

success of public health measures taken to control and prevent

viral hepatitis. An important element in the ISVHLD is the inclusion

of clinicians, investigators, and public health experts from all areas

of the world, including developing nations where viral hepatitis

contributes considerably to morbidity and mortality. The purpose

is to provide stimulus for future researches and collaborations that

promote control of viral hepatitis worldwide.

Shanghai,

China

http://www.isvhld

2012.org

9th European

Health

Promotion

Conference

International

Union for

Health

Promotion

and Education

(IUHPE)

27-29

September

2012

Tallinn,

Estonia

BASL (British

Association

for the Study

of the Liver)

Annual

BASL September

Research

community,

scientists and

clinicians

In 2012, BASL will be represented at the Digestive Disorders

Foundation Meeting, to be held 17-20 June at the ACC, Liverpool.

The BASL meeting consists of both clinical and basic science

symposia, two state of the art talks, update lectures on

contentious issues as well as selected oral and poster

presentations.

UK

http://www.basl.o

rg.uk/annual-

meeting/

Global

Symposium

on Health

Systems

Research

Annual

An

international

steering

committee

made of

various

organisations

31st Oct - 3rd

Nov

Researchers,

policy-makers,

funders,

implementers, civil

society and media

representatives,

and other

stakeholders

To review the status of HSR since the last Symposium in Montreux

(November 2010), to share new evidence, identify new

opportunities and gaps, build understanding across disciplinary

boundaries, and discuss the way forward to support HSR and the

use of evidence in decision-making in low- and middle-income

countries.

Beijing, China http://www.hsr-

symposium.org/

European

Public Health

Conference

Annual

EUPHA,

ASPHER and

the Malta

8-10

November

2012

Researchers,

policy makers, and

practitioners in

Aims to contribute to the improvement of public health in Europe

by offering a means for exchanging information and a platform for

debate

Portomaso,

St. Julian’s,

Malta

http://www.eupha

.org/site/upcomin

g_conference.php

20101105_D02-03_PMT_EN_PS.pdf

19

Association of

Public Health

Medicine

(MAPHM)

the field of public

health and health

services research

as well as public

health training

and education in

Europe.

Young

Researchers

Forum.

Annual ASPHER November Research

community

A unique opportunity for MPH, PhD and postdoc researchers to

present their work to a select audience of peers and key

representatives of the European public health community

http://www.old.as

pher.org/index.ph

p?site=young_rese

archers_forum&P

HPSESSID=e33ac2a

ec8a6d901b48c48f

feec3996c

European

Scientific

Conference

on Applied

Infectious

Disease

Epidemiology

(ESCAIDE),

Annual ECDC November

2012

Infectious Disease

epidemiologists,

research

community

uneven years

in Stockholm,

even years

other EU city

Global Forum

on Migration

and

Development

Annual

The host

country

(Chair-in-

Office)

assumes

responsibility

for the

preparatory

process and

the

implementati

on of each

Forum

Meetings

throughout

2012 but

main summit:

21-22

November

2012

Civil Society,

representatives of

NGOs, migrant

associations,

diaspora

organizations, and

representatives of

trade unions and

the private sector

Theme 2012: Securing development through achievable

improvement of migrants’ well-being.

The largest and most comprehensive global platform for dialogue

and cooperation on international migration and development.

Informal and voluntary dialogue among countries on current and

emerging migration and development issues. Two parts: 1)

provides a platform for discussion among representatives of Civil

Society, representatives of NGOs, migrant associations, diaspora

organizations, and representatives of trade unions and the private

sector that are associated with, or interested in migration and

development issues. 2) open to all UN Member States and

Observers. In general, participants in the Government Meeting are

high-level policy makers and practitioners on the ground, who can

discuss informally the complex issues relating to migration and

development.

Open to all UN Member States and Observers.

Port Louis,

Mauritius

http://www.gfmd.

org/en/gfmd-at-a-

glance.html

20101105_D02-03_PMT_EN_PS.pdf

20

Facilitating internal communication

The Coordinator and Work Package Leaders will make sure that all information and knowledge generated

in the project are widely circulated internally among the participants.

Progress reporting is also scheduled as part of internal communication activities, with updates required

from Work Package teams each quarter.

The website is an important internal communication source and tool and a members only facility

allowing on-line access to all documents, including meeting and progress updates has been made

available.

Project partners will also be encouraged to provide content for the bulletins, which should lead to more

diverse content.

20101105_D02-03_PMT_EN_PS.pdf

21

Requirements for external communications:

As the project is funded by the EU, there are certain aspects that are mandatory for all external

communication activities:

� The Coordinator is resposible for all external communication activities and approval should be

sought before publishing or making publicly available any material relating to HEPscreen. This is to

ensure consistency with this strategy but also to ensure compliance with EU standards;

� The HEPscreen logo and strapline (Screening for hepatitis B and C among migrants in the

European Union) should be used on all materials (with the exception of scientific papers)

produced as a result of the project. The use of partner logos alongside the HEPscreen logo needs

prior approval from the coordinator;

� Only the EU logo is to be used, not the EAHC or the Framework for Health;

� The following clause must be included if any reference is made to the EU as funders, to the

Framework for Health Programme or the EAHC/DG SANCO:

� “The EU HEP SCREEN project has received funding from the European Commission

under the Health Programme 2008-2013. However, the sole responsibility for the

study lies with the author and the European Commission is not responsible for any

use that may be made of the information contained therein"

� All interaction with the press or media should be routed through the Coordinator. Press releases

produced by project partners alone without prior consortium approval is not encouraged.

� Proactive attendance at conferences to promote the work of HEPscreen and raise awareness of

the activities is a key part of dissemination and is encouraged by all partners.

SCREENING FOR HEPATITIS B AND CAMONG MIGRANTS IN THE EUROPEAN UNION

Chronic infection with hepatitis B and C can cause serious liver disease. Advances in treatment means this can now be prevented. But we still need to fi nd out who is infected. People born in endemic countries are an important risk group.

TheHEPscreenToolkithasbeen

developedthroughresearchincluding

pilotstudiesandaimstomotivate

andenableotherstorespondtothis

publichealthchallengethroughthe

implementationofeffectivescreening.

Visit the HEPscreen Toolkit

www.hepscreen.eu

In the HEPscreen Toolkit you can find:

Videosandanimationsaboutthepublichealthchallengeofchronicviralhepatitis

Epidemiologicaltoolstoassesstheburdenofchronicviralhepatitisamongmigrants

Howto…guidesandcasestudiesaboutthedifferentwaysofscreeningamongmigrants

Arepositoryofgoodpracticescreeningprojects

Atooltocreatemulti-lingualleafletsforpeopleofferedscreening-over40languagesavailable

Apre-testdiscussionchecklistforhealthprofessionsofferingscreening

Goodpracticerecommendationsforpost-testcounsellingandlinkagetospecialistcare

APolicySummaryarticle

Scientificarticlesandposters

Co-funded bythe Health Programmeof the European Union

20101105_D02-05_PMT_EN_PS

1

HEPscreen WP2: Overview of presentations at local, national and international meetings and conferences 2011 – 2014

Final conference

Conference Date Place Topic

HEPscreen final conference (Side meeting at HepHIV 2014 conference) October 2014 Barcelona, Spain HEPscreen results and toolkit

Oral presentations at scientific conferences


Holland Fuse Conference April 2013 Noordwijkerhout, Netherlands WP4: Guidelines

European Public Health Conference (EUPHA) November 2013 Brussels, Belgium WP4: Burden of disease

EUPHA Migrant and Ethnic Minority Health conference April 2014 Granada, Spain HEPscreen workshop

EUPHA Migrant and Ethnic Minority Health conference April 2014 Granada, Spain WP6: Pilot Barcelona

HepHIV2014 conference October 2014 Barcelona, Spain WP4: Vaccination

HepHIV2014 conference October 2014 Barcelona, Spain WP4: Referral

HepHIV2014 conference October 2014 Barcelona, Spain WP6: Pilot Barcelona

Poster presentations at scientific conferences


45th

National Conference of the Italian Society of

Hygiene, Preventive Medicine and Public Health October 2012 Cagliare, Italy WP4: Referral and counselling

EASL International Liver Conference March 2013 Amsterdam, Netherlands WP4: Treatment restrictions

EASL International Liver Conference March 2013 Amsterdam, Netherlands WP4: Guidelines

EASL International Liver Conference March 2013 Amsterdam, Netherlands WP5: Good examples in screening

46th


Hygiene, Preventive Medicine and Public Health October 2013 Taormina, Italy WP4: Referral

46th


Hygiene, Preventive Medicine and Public Health October 2013 Taormina, Italy WP4: Counselling

European Public Health Conference November 2013 Brussels, Belgium WP4: Access to treatment

EUPHA Migrant and Ethnic Minority Health conference April 2014 Granada, Spain WP4: Screening practices

20101105_D02-05_PMT_EN_PS

2

EUPHA Migrant and Ethnic Minority Health conference April 2014 Granada, Spain WP4: Translation services

HepHIV2014 conference October 2014 Barcelona, Spain WP4: Screening practices

HepHIV2014 conference October 2014 Barcelona, Spain WP4; Access to treatment

HepHIV2014 conference October 2014 Barcelona, Spain WP6: Pilot Grampian

Presentations at other international conferences and meetings

Conference / meeting Date Place Topic

Correlation conference December 2011 Ljubljana, Slovenia HEPscreen

Minorities, Communities and BBVs Conference March 2013 Glasgow, Scotland HEPscreen

EASL International Liver Conference, Posters at EU Health

Programme stand March 2013 Amsterdam, Netherlands Design of the pilot studies

Seminar Competence Center Gesundheit HAW Hamburg April 2013 Hamburg, Germany HEPscreen

2nd Hepatitis B and C Network Meeting, ECDC April 2013 Stockholm, Sweden HEPscreen

Final Conference HIV-COBATEST Project September 2013 Barcelona, Spain HEPscreen

Public health benefits of screening for infectious diseases

among newly arrived migrants to the EU/EEA (ECDC meeting) March 2014 Athens, Greece HEPscreen

EU health programme workshop at HepHIV2014 conference October 2014 Barcelona, 2014 HEPscreen

Presentations at other local or national conferences and meetings

Conference / meeting Date Place Topic

Academic workplace Rotterdam meeting August 2012 Rotterdam, Netherlands HEPscreen

National symposium ‘HBV-HCV knowledge 2014’ April 2014 Bilthoven, Netherlands HEPscreen

Infectious Disease Doctors in Training Research Meeting April 2014 Rotterdam, Netherlands WP4 Results

Infectious Disease Section Discussion Meeting July 2014 Rotterdam, Netherlands WP4: Access to Treatment

Hepatitis meeting for Public Health Services in the Netherlands October 2014 Bilthoven, Netherlands HEPscreen toolkit

Infectious Disease Doctors in Training Research Meeting October 2014 Rotterdam, Netherlands HEPscreen toolkit

Annual Scottish Public Health Conference of UK Faculty of Public Health November 2014 Aviemore, Scotland Grampian pilot

Viral Hepatitis Symposium December 2014 Edinburgh, Scotland HEPscreen

Documents

Screening for chronic viral hepatitis in migrant populations · PDF fileimprove the awareness, understanding and health-seeking behaviour of this audience ... migrant and ethnic minority